- CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024
- CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
- CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
- CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
Key statistics
As of last trade CERo Therapeutics Holdings Inc (CERO:NMQ) traded at 0.1747, 5.88% above its 52-week low of 0.165, set on Jul 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.191 |
---|---|
High | 0.1963 |
Low | 0.1683 |
Bid | 0.1731 |
Offer | 0.1751 |
Previous close | 0.256 |
Average volume | 16.43m |
---|---|
Shares outstanding | 20.67m |
Free float | 9.87m |
P/E (TTM) | -- |
Market cap | 5.29m USD |
EPS (TTM) | -0.3796 USD |
Data delayed at least 15 minutes, as of Jul 29 2024 15:22 BST.
More ▼